Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

KEYNOTE-042 Investigators, Iveta Kudaba, Gunta Purkalne

Research output: Contribution to journalArticlepeer-review

1302 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences